PMID- 30586664
OWN - NLM
STAT- MEDLINE
DCOM- 20190509
LR  - 20190509
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 67
DP  - 2019 Feb
TI  - Maturation of dendritic cells by maitake alpha-glucan enhances anti-cancer effect of 
      dendritic cell vaccination.
PG  - 408-416
LID - S1567-5769(18)30790-2 [pii]
LID - 10.1016/j.intimp.2018.12.039 [doi]
AB  - Dendritic cells (DCs) play a primary role in antigen presentation to CD4(+) and 
      CD8(+) T cells and induce acquired immune response against cancer cells. 
      Therefore, determining positive modulators of DC activation to improve 
      therapeutic approaches for cancer immunotherapy is greatly needed. In this study, 
      we investigated the effect of maitake alpha-glucan YM-2A, isolated from Grifola 
      frondosa, on the maturation and function of DCs and its adjuvant effect on a 
      tumor-associated antigen (TAA)-loaded DC vaccine against murine tumor. We showed 
      that YM-2A induced morphological changes and increased cell-surface maturation 
      markers and cytokine production in DCs. In a mixed lymphocyte reactions assay, 
      YM-2A-treated DCs increased proliferation and production of IFN-gamma by allogeneic 
      CD4(+) and CD8(+) T cells. These results indicate that YM-2A phenotypically and 
      functionally activates DCs. Furthermore, YM-2A-treated TAA-loaded DC vaccine 
      significantly reduced tumor growth and improved survival in two murine tumor 
      models, CT-26 tumor-bearing BALB/c mice and B16 melanoma-bearing C57BL/6 mice. 
      YM-2A-treated TAA-loaded DC vaccine increased splenic IFN-gamma producing CD4(+) and 
      CD8(+) T cells in CT-26 tumor-bearing BALB/c mice. Antibody neutralization 
      studies indicated that YM-2A-induced DC maturation is mediated, in part, by the 
      Dectin-1-dependent pathway. Overall, YM-2A-treatment with a TAA-loaded DC vaccine 
      could be an excellent candidate for immunotherapy against cancer.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Masuda, Yuki
AU  - Masuda Y
AD  - Department of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Japan.
FAU - Nakayama, Yoshiaki
AU  - Nakayama Y
AD  - Department of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Japan.
FAU - Mukae, Takehiro
AU  - Mukae T
AD  - Department of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Japan.
FAU - Tanaka, Akihiro
AU  - Tanaka A
AD  - Research and Development Department, Yukiguni Maitake Co., Ltd., Niigata, Japan.
FAU - Naito, Kenta
AU  - Naito K
AD  - Research and Development Department, Yukiguni Maitake Co., Ltd., Niigata, Japan.
FAU - Konishi, Morichika
AU  - Konishi M
AD  - Department of Microbial Chemistry, Kobe Pharmaceutical University, Kobe, Japan. 
      Electronic address: mkonishi@kobepharma-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20181231
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Cancer Vaccines)
RN  - 0 (Glucans)
RN  - 0 (Lectins, C-Type)
RN  - 0 (dectin 1)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - CD4-Positive T-Lymphocytes
MH  - CD8-Positive T-Lymphocytes
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/*drug effects/immunology/physiology
MH  - Female
MH  - Glucans/chemistry/*pharmacology
MH  - Grifola/*chemistry
MH  - Interferon-gamma/genetics/metabolism
MH  - Lectins, C-Type/metabolism
MH  - Mice
MH  - Neoplasms, Experimental/*therapy
OTO - NOTNLM
OT  - Alpha-glucan
OT  - Cancer immunotherapy
OT  - Dendritic cell vaccination
OT  - Grifola frondosa
OT  - Maitake mushroom
EDAT- 2018/12/27 06:00
MHDA- 2019/05/10 06:00
CRDT- 2018/12/27 06:00
PHST- 2018/10/01 00:00 [received]
PHST- 2018/11/30 00:00 [revised]
PHST- 2018/12/14 00:00 [accepted]
PHST- 2018/12/27 06:00 [pubmed]
PHST- 2019/05/10 06:00 [medline]
PHST- 2018/12/27 06:00 [entrez]
AID - S1567-5769(18)30790-2 [pii]
AID - 10.1016/j.intimp.2018.12.039 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Feb;67:408-416. doi: 10.1016/j.intimp.2018.12.039. Epub 
      2018 Dec 31.